title: Reversal of the malignant phenotype by an anti-ras ribozyme.
abstract: In this study a ribozyme (catalytic RNA) was designed to site specifically cleave the mRNA of the activated H-ras gene expressed in human bladder carcinoma EJ cells. The optimal conditions for catalytic cleavage by the ribozyme were demonstrated in vitro. A synthetic DNA encoding the ribozyme was cloned into a mammalian expression vector (pH beta APr-1) and transfected into EJ cells. The expressed ribozyme significantly altered the morphology and suppressed the growth of EJ cells in vitro. These cell lines were examined for their malignant potential in athymic (nude) mice by an orthotopic (transurethral) implantation model, which recapitulates the invasive potential of various bladder carcinomas. EJ tumors expressing the H-ras ribozyme were characterized by a marked reduction in tumor take and invasion compared to those formed by control EJ cells. These differences resulted in almost a twofold increase in survival of mice implanted with ribozyme-containing EJ cells. These results further elucidate the role of ras genes in tumorigenicity and invasion, as well as introduce ribozymes as a new class of anticancer agents.
authors.affiliation: Department of Medical Oncology, Beckman Research Institute, Duarte, California.
authors.forename: M
authors.initials: M
authors.lastname: Kashani-Sabet
authors.forename: T
authors.initials: T
authors.lastname: Funato
authors.forename: T
authors.initials: T
authors.lastname: Tone
authors.forename: L
authors.initials: L
authors.lastname: Jiao
authors.forename: W
authors.initials: W
authors.lastname: Wang
authors.forename: E
authors.initials: E
authors.lastname: Yoshida
authors.forename: B I
authors.initials: BI
authors.lastname: Kashfinn
authors.forename: T
authors.initials: T
authors.lastname: Shitara
authors.forename: A M
authors.initials: AM
authors.lastname: Wu
authors.forename: J G
authors.initials: JG
authors.lastname: Moreno
mesh_terms: D000818:Animals; D001483:Base Sequence; D015152:Blotting, Northern; D015153:Blotting, Western; D002460:Cell Line; D003001:Cloning, Molecular; D005813:Genes, Synthetic; D011905:Genes, ras; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D009368:Neoplasm Transplantation; D009690:Nucleic Acid Conformation; D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense / Q000138:chemical synthesis; D010641:Phenotype; D010957:Plasmids; D016133:Polymerase Chain Reaction; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis / Q000235:genetics; D016337:RNA, Catalytic / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics / Q000302:isolation & purification; D014162:Transfection; D014183:Transplantation, Heterologous; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology
chemical_list: D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic; D012333:RNA, Messenger; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)